NASDAQ: CYCCP - Cyclacel Pharmaceuticals, Inc.

Rentabilität für sechs Monate: -31.24%
Dividendenrendite: +2.99%
Sektor: Healthcare

Aktionsplan Cyclacel Pharmaceuticals, Inc.


Über das Unternehmen Cyclacel Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors.

weitere details
It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

IPO date 2005-11-30
ISIN US23254L2079
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 2.99
Дивиденд ао 0.6
Сайт https://www.cyclacel.com
Цена ао 18.2
Preisänderung pro Tag: 0% (6.47)
Preisänderung pro Woche: +6.94% (6.05)
Preisänderung pro Monat: -4.15% (6.75)
Preisänderung über 3 Monate: -7.57% (7)
Preisänderung über sechs Monate: -31.24% (9.41)
Preisänderung pro Jahr: -60.36% (16.32)
Preisänderung über 3 Jahre: -19.13% (8.0001)
Preisänderung über 5 Jahre: +1 152.18% (0.5167)
Preisänderung über 10 Jahre: 0% (6.47)
Preisänderung seit Jahresbeginn: -13.73% (7.5)

Unterschätzung

Name Bedeutung Grad
P/S 34.42 1
P/BV 23.81 1
P/E 0 0
EV/EBITDA -0.3672 0
Gesamt: 3.5

Effizienz

Name Bedeutung Grad
ROA, % -256.16 0
ROE, % -3715.82 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 2.99 7.48
DSI 0.8571 8.57
Gesamt: 5.15

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.0012 10
Gesamt: 10

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % -50.18 0
Rentabilität Ebitda, % 159.41 10
Rentabilität EPS, % 5522790.8 10
Gesamt: 7.6

Institutionen Volumen Aktie, %
Sound Income Strategies, LLC 182 14.46
UBS Group AG 17 1.35



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Mr. Spiro George Rombotis President, CEO & Executive Director 612.47k 1959 (66 Jahre)
Mr. Paul McBarron Executive VP of Finance, CFO, COO, Secretary & Executive Director 321.61k 1961 (64 Jahr)
Ms. Gill Christie Director of Human Resources N/A 1957 (68 Jahre)
Dr. Brian Schwartz M.D. Chief Medical Officer & Director 53k 1962 (63 Jahr)
Grace Kim Investor Relations Executive N/A

Adresse: United States, Berkeley Heights. NJ, 200 Connell Drive - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.cyclacel.com